Evidence map›Paper›PMID 29533123›Full record

ArticleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2019

Protective effects of sulforaphane in experimental vascular cognitive impairment: Contribution of the Nrf2 pathway.

Leilei Mao, Tuo Yang, Xin Li, Xia Lei, Yang Sun, Yongfang Zhao, Wenting Zhang, Yanqin Gao, Baoliang Sun, Feng Zhang

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 96 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Role of NRF2 in Pathogenesis of Alzheimer's Disease.Antioxidants (Basel, Switzerland) · 2024
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Leilei Mao1 Department of Neurology, School of Medicine, Pittsburgh Institute of Brain Disorders and Recovery, University of Pittsburgh, Pittsburgh, PA, USA.
Tuo Yang1 Department of Neurology, School of Medicine, Pittsburgh Institute of Brain Disorders and Recovery, University of Pittsburgh, Pittsburgh, PA, USA.
Xin Li2 Key Laboratory of Cerebral Microcirculation, Taishan Medical University, Tai'an, Shandong, China.
Xia Lei2 Key Laboratory of Cerebral Microcirculation, Taishan Medical University, Tai'an, Shandong, China.
Yang Sun1 Department of Neurology, School of Medicine, Pittsburgh Institute of Brain Disorders and Recovery, University of Pittsburgh, Pittsburgh, PA, USA.
Yongfang Zhao3 State Key Laboratory of Medical Neurobiology and Institute of Brain Science, Fudan University, Shanghai, China.
Wenting Zhang3 State Key Laboratory of Medical Neurobiology and Institute of Brain Science, Fudan University, Shanghai, China.
Yanqin Gao1 Department of Neurology, School of Medicine, Pittsburgh Institute of Brain Disorders and Recovery, University of Pittsburgh, Pittsburgh, PA, USA.
Baoliang Sun2 Key Laboratory of Cerebral Microcirculation, Taishan Medical University, Tai'an, Shandong, China.
Feng Zhang1 Department of Neurology, School of Medicine, Pittsburgh Institute of Brain Disorders and Recovery, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0001-7275-9989
University of Pittsburgh · USTaishan Medical University · CNFudan University · CN

Funding

A novel mechanism of neurovascular protection in ischemic toleranceR01NS092810 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZHANG, FENG · 2015 to 2020
$1.7M
NINDS NIH HHS R01 NS092810
6 · The paper itself

Abstract

The major pathophysiological process of vascular cognitive impairment (VCI) is chronic cerebral ischemia, which causes disintegration of the blood-brain barrier (BBB), neuronal death, and white matter injury. This study aims to test whether sulforaphane (Sfn), a natural activator of nuclear factor erythroid 2-related factor 2 (Nrf2), reduces the chronic ischemic injury and cognitive dysfunction after VCI. Experimental VCI was induced in rats by permanent occlusion of both common carotid arteries for six weeks. This procedure caused notable neuronal death in the cortex and hippocampal CA1, myelin loss in the corpus callosum and hippocampal fimbria, accumulation of myelin debris in the corpus callosum, and remarkable cognitive impairment. Sfn treatment alleviated these ischemic injuries and the cognitive dysfunction. Sfn-mediated neuroprotection was associated with enhanced activation of Nrf2 and upregulation of heme oxygenase 1. Sfn also reduced neuronal and endothelial death and maintained the integrity of BBB after oxygen-glucose deprivation in vitro in an Nrf2 dependent manner. Furthermore, Nrf2 knockdown in endothelial cells decreased claudin-5 protein expression with downregulated claudin-5 promoter activity, suggesting that claudin-5 might be a target gene of Nrf2. Our results demonstrate that Sfn provides robust neuroprotection against chronic brain ischemic injury and may be a promising agent for VCI treatment.

Indexed as

BrainBrain IschemiaCognitive DysfunctionAnimalsCell DeathChronic DiseaseClaudin-5Endothelial CellsGene Expression Regulation, EnzymologicHeme Oxygenase (Decyclizing)IsothiocyanatesMaleNeuronsNF-E2-Related Factor 2RatsRats, Sprague-DawleyClaudin-5Cldn5 protein, ratHeme Oxygenase (Decyclizing)Hmox1 protein, ratIsothiocyanatesNfe2l2 protein, ratNF-E2-Related Factor 2sulforaphaneSulfoxidesDementiahypoperfusionischemic toleranceneurovascular unittight junction

Identifiers

PMID29533123
PMCPMC6365596
OpenAlexW2789559031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.